Kazia Therapeutics Files September 2025 6-K Report
Ticker: KZIA · Form: 6-K · Filed: Sep 11, 2025 · CIK: 1075880
Sentiment: neutral
Topics: regulatory-filing, foreign-private-issuer, compliance
TL;DR
Kazia Therapeutics (KZA) filed its monthly 6-K report on 9/11/25, standard procedure for foreign issuers.
AI Summary
Kazia Therapeutics Limited filed a Form 6-K on September 11, 2025, reporting for the month of September 2025. The company, previously known as Novogen Ltd, is incorporated in Australia and has its principal executive offices in Sydney, NSW. This filing is a routine report for a foreign private issuer.
Why It Matters
This filing indicates ongoing reporting compliance for Kazia Therapeutics, a foreign private issuer, which is important for investors tracking the company's regulatory activities.
Risk Assessment
Risk Level: low — This filing is a routine report of foreign private issuer status and does not contain new material financial or operational information.
Key Players & Entities
- Kazia Therapeutics Limited (company) — Registrant
- Novogen Ltd (company) — Former company name
- September 11, 2025 (date) — Filing date
- Sydney NSW (location) — Principal executive office location
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers required to be filed with the SEC to provide information that the issuer makes or is required to make public pursuant to the laws of its home country, or that it files or is required to file with a stock exchange on which its securities are traded.
When was Kazia Therapeutics Limited previously known as?
Kazia Therapeutics Limited was formerly known as Novogen Ltd, with a date of name change on December 28, 1998.
Where are Kazia Therapeutics Limited's principal executive offices located?
The principal executive offices of Kazia Therapeutics Limited are located at Three International Towers, Level 24, 300 Barangaroo Avenue, Sydney NSW 2000.
Does Kazia Therapeutics Limited file annual reports under Form 20-F or Form 40-F?
Kazia Therapeutics Limited indicates that it files annual reports under cover of Form 20-F.
What is the SIC code for Kazia Therapeutics Limited?
The Standard Industrial Classification (SIC) code for Kazia Therapeutics Limited is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 295 words · 1 min read · ~1 pages · Grade level 13.7 · Accepted 2025-09-11 09:11:46
Filing Documents
- d98475d6k.htm (6-K) — 10KB
- d98475dex991.htm (EX-99.1) — 12KB
- 0001193125-25-200822.txt ( ) — 23KB
From the Filing
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2025 Commission File Number 000-29962 Kazia Therapeutics Limited (Translation of registrant's name into English) Three International Towers Level 24 300 Barangaroo Avenue Sydney NSW 2000 (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-FForm 40-F Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): INFORMATION CONTAINED IN THIS FORM 6-K REPORT On September 11, 2025, Kazia Therapeutics Limited (the "Company") issued a press release titled "Kazia Therapeutics Reports Complete Ex Vivo Disruption of Large Circulating Tumor Cell Clusters in Stage IV HER2-Positive Breast Cancer with Paxalisib Monotherapy." A copy of this release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The Company hereby incorporates by reference the information contained herein, including Exhibit 99.1, except for the quote of Dr. John Friend, Chief Executive Officer of the Company, contained in Exhibit 99.1, into the Company's registration statement on Form F-3 (File No. 333-281937). EXHIBIT LIST Exhibit Description 99.1 Press Release of Kazia Therapeutics Limited dated September 11, 2025 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Kazia Therapeutics Limited (Registrant) /s/ John Friend John Friend Chief Executive Officer Date: September 11, 2025